Showing results (1-10 of 318) with videos related to
Sort By:
Pageof 32
Oncotargets and Therapy|September 10, 2019
Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancerShouzheng Wang, Junling LiSustainable Cities and Society|May 27, 2022
Challenges and coping strategies of online learning for college students in the context of COVID-19: A survey of Chinese universitiesJunling Li, Wanyu CheZhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|January 22, 2021
[Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer
with Rare Mutation]Teng Li, Junling LiZhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 21, 2016
[Clinical Significance of Tumor Marker Detection in Patients
with Advanced Squamous Cell Carcimoma of the Lung]Ping Liang, Junling LiZhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 21, 2016
[Driven Gene in Patients with Lung Squamous Cell Carcinoma:
Analysis of Clinicopathologic Characteristics and Prognosis]Tongtong Zhang, Junling LiZhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 21, 2016
[Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer]Shouzheng Wang, Junling LiZhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|May 26, 2021
[Review on the Combination Strategy of Anti-angiogenic Agents
and Other Anti-tumor Agents in Advanced Non-small Cell Lung Cancer]Ziyi Xu, Junling LiNitric Oxide : Biology and Chemistry|January 13, 2009
The role of sulfur dioxide as an endogenous gaseous vasoactive factor in synergy with nitric oxideJunling Li, Ziqiang MengArchives of Biochemistry and Biophysics|October 10, 2007
Vasodilatation of sulfur dioxide derivatives and signal transductionZiqiang Meng, Yi Li, Junling LiCancer Innovation|December 13, 2023
PD-L1 blockade by immune checkpoint inhibitors impairs sensitivity to osimertinib in EGFR-mutant non-small cell lung cancer cellsDantong Sun, Puyuan Xing, Junling LiPageof 32